ArticleJournal of medical biochemistry2025
Comparative analysis of plasma folate, homocysteine and erythrocyte folate levels in pregnant women after folic acid administration during different pregnancies.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To examine and evaluate the alterations in plasma folate, homocysteine (HCY), and erythrocyte folate (FOA) concentrations among expectant mothers following folic acid supplementation in distinct pregnancies. Methods: A retrospective analysis was conducted with 416 pregnant women, divided into two groups: an observation group (n=210) who consistently took folic acid throughout pregnancy, and a control group (n=206) who only supplemented during early pregnancy. Key outcomes included plasma folate, HCY, and FOA levels, as well as pregnancy complications and neonatal outcomes. Results: Plasma folate levels were significantly higher in the observation group (10.42±2.96 ng/mL) compared to the control group (7.51±1.58 ng/mL, P<0.001). HCY levels were lower in the observation group (6.54±1.51 mmol/L) versus the control group (10.58±1.27 mmol/L, P<0.001). FOA levels were also higher in the observation group (486.42±105.29 ng/mL) compared to the control (430.20±75.12 ng/mL, P<0.001). The observation group had reduced rates of cesarean section (26.19% vs. 36.41%, P=0.025), anemia (3.81% vs. 8.74%, P=0.038), and hypertension during pregnancy (5.24% vs. 11.65%, P=0.018). Pearson correlation analysis showed a positive correlation between plasma folate and FOA (r=0.116, P<0.05) and negative correlations between plasma folate and HCY (r=-0.411, P<0.05) and between FOA and HCY (r=-0.286, P<0.05). The observation group had significantly lower FBG and P2BG levels and a reduced incidence of gestational anemia and HIP compared to the control group (P<0.05). Cesarean sections were also less frequent in the observation group. Newborns in the observation group had significantly greater height, weight, head circumference, and chest circumference than those in the control group (P<0.05). Conclusions: Consistent folic acid supplementation throughout pregnancy significantly improves maternal folate status, decreases pregnancy-related complications, and enhances neonatal health outcomes. These findings underscore the need for continuous folic acid intake during pregnancy, which could inform clinical guidelines and public health policies to optimize maternal and neonatal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.